How should dexmedetomidine and clonidine be prescribed in the critical care setting?

Cardiac, ventilatory and kidney management in the critical care setting has been optimized over the past decades. Cognition and sedation represent one of the last remaning challenges. As conventional sedation is suboptimal and as the sedation evoked by alpha-2 adrenergic agonists (“cooperative” sedation with dexmedetomidine, clonidine or guanfacine) represents a valuable alternative, this manuscript covers three practical topics for which evidence-based medicine is lacking: a) Switching from conventional to cooperative sedation (“switching”): the short answer is the abrupt withdrawal of conventional sedation, immediate implementation of alpha-2 agonist infusion and the use of “rescue sedation” (midazolam bolus[es]) or “breakthrough sedation” (haloperidol bolus[es]) to stabilize cooperative sedation. b) Switching from conventional to cooperative sedation in unstable patients (e.g., refractory delirium tremens, septic shock, acute respiratory distress syndrome, etc.): to avoid hypotension and bradycardia evoked by sympathetic deactivation, the short answer is to maintain the stroke volume through volume loading, vasopressors and inotropes. c) To avoid these switches and associated difficulties, alpha-2 agonists should be considered first-line sedatives. The short answer is to administer alpha-2 agonists slowly from admission or endotracheal intubation up to stabilized cooperative sedation. The “take home” message is as follows: a) alpha-2 agonists are jointly sympathetic deactivators and sedative agents; b) sympathetic deactivation implies maintaining the stroke volume and iterative assessment of volemia. Evidence-based medicine should document our propositions.


INTRODUCTION
Circulatory, ventilatory, renal and metabolic management has progressed over the decades, but cognition and sedation are lagging behind. During this interval, the following reversals have occurred: from no sedation to general anesthesia (GA)/deep conventional sedation, (1) to interrupted sedation and back (2) to minimal sedation. (3) Minimal sedation is possible, given repeated nursing reassurance ("reassurance") and a provision for deeper sedation. (3,4) Cardiac, ventilatory and kidney management in the critical care setting has been optimized over the past decades. Cognition and sedation represent one of the last remaning challenges. As conventional sedation is suboptimal and as the sedation evoked by alpha-2 adrenergic agonists ("cooperative" sedation with dexmedetomidine, clonidine or guanfacine) represents a valuable alternative, this manuscript covers three practical topics for which evidence-based medicine is lacking: a) Switching from conventional to cooperative sedation ("switching"): the short answer is the abrupt withdrawal of conventional sedation, immediate implementation of alpha-2 agonist infusion and the use of "rescue sedation" (midazolam bolus[es]) or "breakthrough sedation" (haloperidol bolus[es]) to stabilize cooperative sedation. b) Switching from conventional to cooperative sedation in unstable patients (e.g., refractory delirium tremens, septic shock, acute respiratory distress syndrome, etc.): to avoid hypotension and bradycardia evoked by sympathetic deactivation, the short answer is to maintain the stroke volume through volume loading, vasopressors and inotropes. c) To avoid these switches and associated difficulties, alpha-2 agonists should be considered first-line sedatives. The short answer is to administer alpha-2 agonists slowly from admission or endotracheal intubation up to stabilized cooperative sedation. The "take home" message is as follows: a) alpha-2 agonists are jointly sympathetic deactivators and sedative agents; b) sympathetic deactivation implies maintaining the stroke volume and iterative assessment of volemia. Evidence-based medicine should document our propositions.
As alpha-2 agonists interfere with the autonomic system and cognition (propofol, etc.), problems arise: a) how to switch from conventional sedation to alpha-2 agonists ("switching"), e.g., in agitated or unstable patients, refractory delirium tremens (DT), circulatory/ventilatory distress, etc.; and b) how can alpha-2 agonists be prescribed as first-line sedatives de novo upon admission? This manuscript addresses the parasympathetic vs. sympathetic systems, circulation, and ventilation.
Evidence-based medicine is scarce regarding the prescription of alpha-2 agonists. A balanced group of stakeholders with a rigorous approach to the development of consensus guidelines should be convened, which is beyond the reach of our group of lay practitioners: despite its biases, this manuscript is published to help physicians who are not familiar with alpha-2 agonists. Presumably, no formal detailed international guidelines may ever be set up with respect to refractory DT, acute cardioventilatory distress, etc. We reviewed the literature (PubMed search terms: alpha-2 agonist, cooperative sedation, critical care, clonidine, dexmedetomidine, guanfacine). Our clinical practice spanning the period of 1980 -2020 in several countries (USA, Québec, Belgium, France) is summarized (Table 1). Physiological, pharmacological and clinical matters have been delineated earlier. (46)(47)(48)

SWITCHING FROM CONVENTIONAL SEDATION TO COOPERATIVE SEDATION
Conventional sedation combines benzodiazepine or short-acting general anesthetics with opioid analgesics. Muscle relaxants are mainly used in the setting of acute respiratory distress syndrome (ARDS), traumatic brain injury, (49) etc. Nevertheless, a) emergence delirium is encountered following deep sedation. However, is this delirium related to the pathology itself, the CCU environment, or conventional sedation? Moreover, b) deep sedation, bordering GA (1), is used in clinical practice for ARDS or increased intracranial pressure (49) without evidence. (50) # After clonidine 300mg p.o., volunteers switch easily from light sleep to wakefulness ("fairly alert") and back. Low dose clonidine (10mg.kg-1) improves memory in aged primates. In the critical care unit, under dexmedetomidine, a) an intubated child plays a game of little horses with his nurse (P Delaire, RN, personal communication), and b) an intubated patient reported ischemic chest pain, allowing for treatment. $ The innate immune system is not considered. Figure 1 -Relationship between smooth muscle activity and the frequency of sympathetic nerve stimuli in capacitance and resistance vessels: frequency-response curve is deduced for resistance (dashed) and capacitance (continuous) in cat skin muscle.
Effects of lumbar vasoconstrictor fiber stimulation calculated as a percentage of the maximum response for the 2 vascular sections. The curve for the capacitance vessels (veins) is to the left: this curve implies more pronounced effects in this section in the low frequency range compared to those in the resistance vessels (arteries). One-third of the regional blood volume is expelled at a low frequency stimulation rate, thus increasing venous return. A fully developed response occurs within 30 -40 s for both resistance and capacitance vessels. Immediate relaxation occurs after cessation of sympathetic stimulation. In contrast, there is delayed relaxation at high rates of sympathetic stimulation; this delayed relaxation could be of relevance after prolonged administration of high-dose noradrenaline, e.g., in septic shock: prolonged vasomotor sympathetic hyperactivity is associated temporally with poor microcirculation. In turn, prolonged impaired microcirculation is associated with increased mortality. Would normalization of vasomotor sympathetic activity back toward baseline levels be observed and improve microcirculation and outcomes in septic shock? Source: Prys-Roberts C. Regulation of the circulation. In: Prys-Roberts C, editor. The circulation in anesthesia: applied physiology and pharmacology. Oxford: Blackwell; 1980. p. 179-207. Figure 7.2, Relationship between smooth muscle activity and the frequency of sympathetic nerve stimuli in capacitance and resistance vessels; p. 184. (21)

Contraindications
Sick sinus syndrome, spontaneous or drug-induced bradycardia, A-V block II/III, uncompensated hypovolemia, liver failure (consider clonidine), renal failure (consider dexmedetomidine unless renal replacement therapy is ongoing or considered) Drug selection Dexmedetomidine is easier to use (shorter half-life); clonidine is easier to use through the oral route in nonintubated patients with delirium tremens; clonidine or guanfacine p.o. transition from i.v. alpha-2 agonists Never use a bolus of alpha-2 agonist: place a "do not bolus" sticker on the iv line of the alpha-2 agonist (65) 1 Stable patient Switching from conventional to cooperative sedation Abrupt withdrawal of conventional sedation followed immediately by i.v. infusion of alpha-2 agonist (dexmedetomidine 1.5μg.kg-1.h-1 or clonidine 2μg.kg-1.h-1 then titration to effect): expect 1 -3 hours (dex) to 2 -6 hours (clonidine) before reaching steady-state cooperative sedation Rescue sedation The administration of high dose alpha-2 agonist is suggested to reach steady state cooperative sedation as early as possible with minimal rescue sedation. Nevertheless, the dose of alpha-2 agonist has to be lowered if appropriate to achieve -2< RASS < 0 as early as possible  (65) When alpha-2 agonists are not sufficient to evoke -2 < RASS < 0 with absence of brisk movement agitation or tremor, supplement with neuroleptics a) Hallucinations: haloperidol bolus 5 -10 mgx4 or 50mg/48mL/24 hours: 2mg.h-1 to be lowered as soon as RASS < -2 NB: consider haloperidol maximal dose: 30mg.d-1; (93) some authors use significantly higher doses b) Agitation: loxapine 100mgx4 through nasogastric tube to be lowered to 75mgx4, then 50mgx4, etc., and stopped as soon as possible Administer neuroleptic as first-line drug (e.g., haloperidol 5mg i.v. or loxapine 100mg through the nasogastric tube) to avoid abrupt agitation upon withdrawal of conventional sedation and before achieving steady-state cooperative sedation; suppress neuroleptics to make treatment as simple as possible as soon as possible NB: monitor QT when administering any neuroleptics Tracheal extubation Alpha-2 agonists do not suppress airway reflexes: a) assess clinical status (ventilation, circulation, infection, inflammation, etc.); b) taper neuroleptics first; c) titrate alpha-2 agonists to -2 < RASS < 0, then extubate under continued administration of alpha-2 agonist titrated to -2 < RASS < 0 Tapering alpha-2 agonists Alpha-2 agonist withdrawal is of rare occurrence: nevertheless, taper i.v. or p.o. alpha-2 agonist over 48 -96 hours; clonidine p.o. or guanfacine p.o are useful here Discharge from CCU Do not discharge the patient early to ward (hallucinations or tremor should be suppressed for > 24 hours): alpha-2 agonists are usually withdrawn on the ward with reintroduction of benzodiazepines, leading to readmission to CCU Shock/circulatory distress Address hypovolemia iteratively Iterative passive leg raising (PLR, figure 2 (121) ) and echocardiography (collapsability of vena cava, etc.; see text) to allow for absence of increase in systemic pressure or in cardiac output following volume loading (e.g., crystalloid bolus 1000mL/70kg patient) Volume loading (1000mL bolus/70kg) as long as there is hypovolemia (a pressure or better a cardiac output response to PLR does not necessarily mean that the patient is hypovolemic; figure 1). (122) The lung is to be kept "dry". Goal: maintenance of stroke volume, (109) diuresis, suppression of mottling, normalization of capillary refill time, lactate, CO2 gap, and SsvcO2 "Start slow, go slow": dexmedetomidine 0.125μg.kg-1.h-1 for 1 h, then increments of 0.125 to 0.375μg.kg-1.h-1 every hour, up to 1.5μg.kg-1.h-1, according to iterative PLR, echocardiography and circulatory response; rescue sedation only if agitation Or clonidine 0.125μg.kg-1.h-1 for 1 h, then increments of 0.125 to 0.375μg.kg-1.h-1 every h, up to 2μg.kg-1.h-1, according to iterative PLR, echocardiography and circulatory response, rescue sedation if agitation Vasopressors and inotropes according to the usual clinical and echocardiographic indications; no increase in vasopressor or inotrope requirement is observed if hypovolemia or ventricular failure is addressed before and during initiation of cooperative sedation Antiarrhythmics (amiodarone, verapamil, beta blockers, etc.) are used as indicated if dosage and speed of administration are reduced by 50-75% AV -atrioventricular; RASS -Richmond Agitation Sedation Scale; CCU -critical care unit; CO2 -carbon dioxide; SsvcO2 -superior vena cava oxygen saturation; PEEP -positive end-expiratory pressure.

Acute cardioventilatory distress
Beyond the goal of the paper aiming at junior staff: stabilize circulation first or ventilation first depending of the clinical situation, and then switch from conventional to cooperative sedation in an itemized manner: "start slow, go slow", as described above, in an overtly cautious manner

Antinociception
Following steady state cooperative sedation, assess pain: visual analog scale (nonintubated patient) or behavioral pain scale (intubated patient); "medical" patients need little antinociception; "surgical" patients require more antinociception

Rescue opioids
Only if needed, after pain assessment, rescue opioid analgesics to be reintroduced sparingly aiming for early spontaneous ventilation, intestinal motility, absence of hyperalgesia

Indications
No "one size fits all" approach: positive indications only (cognitive, ventilatory, circulatory, renal, metabolic effects; absence of innate immune paralysis, etc.)

Contraindications
Dexmedetomidine and clonidine are sympathetic inhibitors in healthy resting supine volunteers. In the CCU, given the increased sympathetic activity, they normalize sympathetic hyperactivity back toward baseline, i.e., sympathetic deactivators, with the following contraindications: -Hypovolemia: See below.
-Bradycardia (spontaneous or drug-induced, e.g., by beta-blockers & ), sick sinus syndrome, atrioventricular block II or III without a pacemaker. -Liver failure (Child-Pugh C): Clonidine and dexmedetomidine are excreted through the kidney and liver, respectively. Moreover, clonidine and dexmedetomidine are useful in the scenarios of liver and kidney failure, respectively. Nevertheless, a) clonidine can be administered in the setting of acute renal failure if renal replacement therapy (RRT) is used, and b) dexmedetomidine can be used in the setting of liver cirrhosis. (62)

Switching in the setting of preoperative, intraoperative and postoperative administration of alpha-2 agonists
Two situations may be considered. If opioid free anesthesia was administered intraoperatively, the alpha-2 agonist has been administered pre-or intraoperatively (see below): given premedication with an alpha-2 agonist (13) or intraoperative administration of an alpha-2 agonist, (76) if intraoperative opioids and general anesthetic administration have been reduced by 50-75%, (13,(77)(78)(79) then cooperative sedation is administered when reaching the CCU if the expected CCU length of stay is > 2 days. The dose of alpha-2 agonists (e.g., clonidine 900mg pre-and intraoperatively for aortic surgery; (80) 4mg.kg-1/15 minutes during the induction of anesthesia for liver transplant (28) ) is usually sufficient to cover the first postoperative day, with provision for opioid-free analgo-sedation and nicardipine (0.5mg to be repeated if needed). Technology addresses volume (pleth variability index, passive leg raising [PLR], echocardiography) or perfusion (ST monitoring, cerebral oxygenation). If, after volume adjustment, the perfusion pressure is a concern, adjuncts (very low dose noradrenaline 0.01 -0.03mg.kg-1.min-1, (81) compression stockings, lower limb elevation) are used to counteract sympathetic deactivation. An additive effect between the incoming alpha-2 agonist and the opioid (69) should be eliminated. ii) If conventional GA has been administered intra-operatively, low-dose alpha-2 agonists will be introduced slowly (e.g., dexmedetomidine 0.4 -0.7mg.kg-1.h-1) to effect.

Titration to effect
The required RASS (-2 < RASS < 0) deserves comments: a) We do not use -2 < RASS < +1 as others do: (23) Stringent absence of restlessness without any regular, repeated, brisk limb movements is required. In our practice, a patient presenting with the rare occurrence of brisk limb movements may present sudden agitation, assume an erect position and withdraw catheters and tubing in the middle of the night. First, to achieve stringent restlessness, alpha-2 agonists are administered up to the ceiling (7)
Refractory DT in nonintubated patients (93) is an issue. Do they require GA + intubation? These patients present short bouts without agitation or restlessness. Thus, young, combative, addicted patients are able to swallow clonidine (p.o. 7.5 -10μg.kg-1; pills crunched or vials in a minimal amount of water) and achieve quietness within 30 -60 minutes. A similar regimen may be used to transition from i.v. dexmedetomidine to oral clonidine (300mg every 6 hours, then 9 hours, then 12 hours, etc.), (105) up to discontinuation. (105) In this respect, guanfacine (Estulic®; half-life: 10 -30 hours or extended-release guanfacine: Intuniv®) may be considered to initiate oral therapy or to transition from i.v. dexmedetomidine to an oral alpha-2 agonist.

Circulatory distress
Given the contraindications (see above), the administration of alpha-2 agonists is inadvisable in the setting of uncontrolled hemorrhage, septic or cardiogenic shock, etc. Indeed, for a short period of time, sympathetic activation is a lifesaver in regards to control of the pathology, and exogenous vasopressors and/or inotropes are required to maintain left ventricular perfusion pressure and/or contractility, in addition to endogenous sympathetic nervous activation. In contrast, AFTER control of acute cardioventilatory distress, then alpha-2 agonists alpha-2 agonists deactivate the prolonged sympathetic hyperactivity observed in the CCU. After circulatory optimization, normalized sympathetic hyperactivity toward baseline may benefit metabolic syndrome, immunoparalysis, etc., e.g., in the following settings: circulatory failure following cardiac surgery (106,107) or low ejection fraction in the medical setting; (18) sepsis; (39) mild, (108) severe (109,110) or refractory (111) septic shock; or unclamping of a liver graft, (28) with lowered noradrenaline requirements.
Sympathetic hyperactivity is normalized back toward baseline by alpha-2 agonists; background activity is lowered.
Drugs combining sedation and sympathetic deactivation modify the circulation and require the following: a) Abrupt withdrawal of conventional sedation with rescue sedation as needed, up to steady-state cooperative sedation. However, in the conditions of low flow or pressure, the requirements for rescue, conventional or cooperative sedation are usually minimal. b) No hypovolemia: Following alpha-2 agonist administration, SV maintenance is required: (109) further volume loading will not evoke any further increase in CO or BP following PLR. To achieve SV maintenance, different protocols were used: 1500mL of fluid; (109) 10mL.kg-1; (65) and a combination of the following: -First, after each bolus (1000mL/70kg) or each increment of alpha-2 agonist, absence of or minimal collapsibility of the vena cava (119,120) and/ or increase in CO or BP following adequate PLR (Figure 2 (121,122) ): PLR separates the volumeresponsive versus nonresponsive patients: the volume-responsive patients are not necessarily in a hypovolemic state and do not necessarily need additional volume. Volume is minimized to prevent increased lung water. (122,123) Nevertheless, following dexmedetomidine, 5 out of 20 patients with septic shock switched from preload independence to preload dependence. (124) This may evoke hypotension within the first 3 hours of administration (125) and suggests iterative circulatory optimization. -Second, the adequacy of CO and microcirculation are addressed: diuresis, capillary refill, mottling, lactate, (28,116,126) O2 arteriovenous difference (127) or superior vena cava oxygen saturation (SsvcO 2 ), carbon dioxide (CO 2 ) gap. c) Slow administration of a low-dose alpha-2 agonist (dexmedetomidine 0.125μg.kg-1.h-1 i.v. increased incrementally to 1.5μg.kg-1.h-1 over 3 -12 hours). We propose this overtly cautious approach and termed it "start slow, go slow", borrowed from the administration of beta-blockers in heart failure (128) (Figure 3). No alpha-2 agonist bolus is ever administered. Indeed, a high alpha-2 agonist concentration (bolus) will first stimulate vascular alpha-1 receptors, leading to paradoxical hypertension. After dilution of the bolus, brain stem alpha-2 receptors are stimulated, deactivating vasomotor sympathetic hyperactivity, enlarging venous capacitance, and reducing venous return (124) (Figure 1). (21) In summary, bolus alpha-2 agonist administration with simultaneous conventional sedation administration or without the iterative assessment of volemia leads to severe bradycardia and hypotension.
Switching from conventional to cooperative sedation in the setting of hypovolemia and vasopressor administration addresses only one circulatory issue. In the setting of ventilatory distress, circulatory distress is intermingled with ventilatory distress: (129) respiratory arrest usually occurs before cardiac arrest and requires addressing ventilatory distress upfront; positive pressure ventilation with positive end-expiratory pressure (PEEP) imposed on hypovolemia worsens circulatory distress.

Switching in a stable patient
Switching is considered for a patient who has recovered from acute respiratory distress, i.e., before switching to spontaneous breathing. Conventional sedation is abruptly withdrawn. Dexmedetomidine was introduced (up to 1.5μg.kg-1.h-1 incrementally over 2 -3 hours or, better, to effect: -2 ≤ RASS ≤ 0; see "circulatory distress"). Rescue sedation is administered if needed.  Figure 1, The best method for passive leg raising, indicating the five rules to be followed; p. 2. (121,122) [creative commons attribution license].
When acceptable, given -2 ≤ RASS ≤ 0, tracheal extubation is achieved without withdrawal of alpha-2 agonists: as alpha-2 agonists do not depress airway reflexes even when very high doses are used, (84,148) the issue is not the dose of alpha-2 agonist that is administered but the degree of alertness versus deep sedation to allow for airway protection and extubation. Continuous NIV+PEEP is conducted under continued alpha-2 agonist administration titrated to -2 ≤ RASS ≤ 0 up to weaning. Antiarrhythmics are relative contraindications: for simplicity, the beta-blockers, verapamil and amiodarone are to be withdrawn over 24 -72 hours. Evidently, if supraventricular arrhythmia occurs during initiation of the alpha-2 agonist, antiarrhythmics should be administered, with the dose and speed of administration half and then titrated to effect. The perfusion pressure and electrolytes are restored. Administration of an alpha-2 agonist is appropriate only after optimization of volemia ( Figure 2). Alpha-2 agonist administration is initiated immediately after the withdrawal of conventional sedation. Usually, low flow or septic confusion makes the transition uneventful. In young, combative patients, rescue sedation (midazolam 3 to 5mg repeated every 5 to 10 minutes) maintains -2 < RASS < 0. In the setting of refractory delirium tremens, neuroleptic administration before the withdrawal of conventional sedation will avoid breakthrough (e.g., loxapine 100mg p.o. or through a nasogastric tube, or haloperidol 50mg/48mL, 2mL.h-1; breakthrough sedation: haloperidol: 5 -10mg bolus). In unstable, hypovolemic, hypotensive, hypoxic patients, the administration of alpha-2 agonists was increased from 0.125 to 1.5mg.kg-1.h-1 over 3 to 12 hours. Iterative passive leg raising and echocardiography allow for incrementing the administration of the alpha-2 agonist: venous return should be appropriate, and the stroke volume should be maintained throughout the administration of the alpha-2 agonist. (109) Opioid-free analgesia in the setting of cooperative sedation avoids respiratory and cognitive depression. Opioids are only used as rescue analgesia.
In summary, the management becomes analytical: administration of an alpha-2 agonist allows one to separate the physiological versus pharmacological factors involved in the management of ventilatory distress (increased inspiratory activity versus depressed or preserved respiratory generator; ataraxia (8,149) versus deep sedation).

Switching in an unstable patient
Switching in a patient presenting with acute cardioventilatory distress under conventional sedation in the CCU involves prioritizing between simultaneous issues beyond the scope of this manuscript: stabilized circulation (see above), stabilized ventilatory distress (very high oxygen flow, NIV versus controlled mandatory ventilation (150) ), then switching from conventional to cooperative sedation (see above).

Acute cardioventilatory distress
Septic shock (158) or early diffuse ARDS (150) are beyond the scope of this section. SARS-CoV-2-ARDS (COVID-ARDS) is an inflammatory disease leading to a high respiratory drive and an inflammatory vascular disease of the pulmonary capillaries. Low or medium PEEP is required, with tight control of temperature, agitation and inflammation Noninvasive ventilation (low PS, (143,(159)(160)(161) high FiO 2 , high PEEP) or very high O 2 flow allows one to buy time, expedite preoxygenation (162) and minimize the work of breathing. Simultaneously, volume loading (e.g., 1000mL bolus before endotracheal intubation: "intubation") prevents the circulatory collapse observed immediately after intubation + positive pressure ventilation + PEEP in hypovolemic patients. (163) If NIV partitions the patients in need of CMV versus NIV, (140) over 30 -60 minutes, alpha-2 agonist infusion may be started before setting up NIV or during NIV. Conversely, alpha-2 agonists are infused immediately after intubation. Rescue or breakthrough sedation is used up to stable cooperative sedation.
The dose of dexmedetomidine is a function of the circulation (see above: 0.125μg.kg-1.h-1 incrementally up to 1.5μg.kg-1.h-1, -2 ≤ RASS ≤ 0 over 3 -12 hours: start slow, go slow). As an extended CCU stay is likely, immediate stable cooperative sedation is not warranted. First, stabilization of the circulation should be achieved (volume vs. vasopressors when the diastolic pressure is low (164) ). Second, iterative rescue sedation allows one to stabilize incremental cooperative sedation. Finally, P-SILI and hypoxemia are addressed (Table 1 of the study by Petitjeans et al. (55) ).
Two issues deserve comment: a) Tolerance to the sedative effects of alpha-2 agonists develops over weeks (148) or days. In addition, septic confusion or low-flow obtundation improved over time. Therefore, the sedation achieved with alpha-2 agonists may become insufficient. Higher doses of alpha-2 agonists may be used. Conversely, supplementation with neuroleptics (see above) achieves -2 < RASS < 0. b) Muscle relaxation suppresses P-SILI and patient-to-ventilator dyssynchrony (165) for 12-48 hours. (51,57,58) Should first-line alpha-2 agonists administered to the ceiling effect be supplemented under muscle relaxation? Awareness will be minimized by iterative clinical examination, electroencephalography (BIS), titration of alpha-2 agonists to effect, reassurance and additional neuroleptics.